GENETIC ELEMENTS TRANSFORMING MOUSE FIBROBLASTS

转化小鼠成纤维细胞的遗传元件

基本信息

  • 批准号:
    7491397
  • 负责人:
  • 金额:
    $ 10.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1994
  • 资助国家:
    美国
  • 起止时间:
    1994-01-03 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal is an extension of ongoing program of development of new functional gene discovery methodologies for identification of cancer-related genes. In the previous phase, it was primarily focused on detection of new candidate tumor suppressor and drug sensitivity genes. Recent methodological advancements made it possible now to focus on prospective molecular anticancer treatment targets (ACTTs) defined as cellular factors, the repression of which leads to selective killing or sensitization to treatment of tumor cells. Candidate ACTT search is based on a combination of three powerful techniques - microarray gene expression analysis, genetic suppressor element (GSE) methodology and newly developed selection-subtraction approach (SSA). These techniques are integrated in one technological pipeline that allows identification of genetic events making tumor cells tolerant to oncogenic Ras. The search for ACTTs will start from collection of a pool of candidate sequences representing genes that become upregulated in a series of populations of human fibroblasts rescued from Ras-mediated growth arrest by different cooperating genetic elements identified in the course of preliminary studies. GSE library will be constructed from the selected sequences and screened, using SSA technique, for the GSEs capable of killing Ras-transformed but not normal fibroblasts. Identified genes will be validated as prospective ACTTs by using siRNA constructs against each individual candidate that will be tested for their specific cytotoxicity for tumor cells. Relevance of identified candidate ACTTs to naturally occurring tumor cells will be characterized and the program will be further extended towards development of small molecules with anticancer properties acting by suppression of identified ACTT. The success of the proposed study will indicate development of a powerful target discovery tool that will be applicable for ACTT identification in other types of cancer.
描述(由申请人提供):该提案是正在进行的开发用于鉴定癌症相关基因的新功能基因发现方法的项目的扩展。在前一阶段,主要集中在检测新的候选肿瘤抑制基因和药物敏感基因。最近的方法学进展使得现在有可能关注被定义为细胞因子的前瞻性分子抗癌治疗靶点(ACTT),其抑制导致选择性杀死肿瘤细胞或对肿瘤细胞的治疗敏感。候选ACTT搜索基于三种强大技术的组合-微阵列基因表达分析,遗传抑制元件(GSE)方法和新开发的选择减法(SSA)。这些技术被整合在一个技术管道中,该技术管道允许鉴定使肿瘤细胞耐受致癌Ras的遗传事件。ACTT的搜索将从收集代表基因的候选序列库开始,这些基因在一系列人成纤维细胞群体中被初步研究过程中鉴定的不同协同遗传元件从Ras介导的生长停滞中拯救出来。将从所选序列构建GSE文库,并使用SSA技术筛选能够杀死Ras转化但不杀死正常成纤维细胞的GSE。通过使用siRNA构建体针对将测试其对肿瘤细胞的特异性细胞毒性的每个个体候选物,将鉴定的基因验证为前瞻性ACTT。将表征鉴定的候选ACTT与天然存在的肿瘤细胞的相关性,并且该计划将进一步扩展到通过抑制鉴定的ACTT发挥抗癌作用的小分子的开发。这项研究的成功将表明一种强大的靶点发现工具的开发,该工具将适用于其他类型癌症的ACTT鉴定。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREI V GUDKOV其他文献

ANDREI V GUDKOV的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREI V GUDKOV', 18)}}的其他基金

"Combining radiation with TLR5 agonist based immunotherapy against liver metastases"
“结合放射治疗和基于 TLR5 激动剂的免疫疗法来对抗肝转移”
  • 批准号:
    9806462
  • 财政年份:
    2019
  • 资助金额:
    $ 10.68万
  • 项目类别:
Mechanisms of mitigation of radiation damage of GI tract by Protectan CBLB502
Protectan CBLB502减轻胃肠道辐射损伤的机制
  • 批准号:
    7938617
  • 财政年份:
    2009
  • 资助金额:
    $ 10.68万
  • 项目类别:
Mechanisms of mitigation of radiation damage of GI tract by Protectan CBLB502
Protectan CBLB502减轻胃肠道辐射损伤的机制
  • 批准号:
    7865476
  • 财政年份:
    2009
  • 资助金额:
    $ 10.68万
  • 项目类别:
Protectan CBLB502
保护素CBLB502
  • 批准号:
    7919056
  • 财政年份:
    2009
  • 资助金额:
    $ 10.68万
  • 项目类别:
Controlling Radiation Injury by TLR5 Agonists
通过 TLR5 激动剂控制放射损伤
  • 批准号:
    7557556
  • 财政年份:
    2008
  • 资助金额:
    $ 10.68万
  • 项目类别:
Controlling Radiation Injury by TLR5 Agonists
通过 TLR5 激动剂控制放射损伤
  • 批准号:
    8103080
  • 财政年份:
    2008
  • 资助金额:
    $ 10.68万
  • 项目类别:
Controlling Radiation Injury by TLR5 Agonists
通过 TLR5 激动剂控制放射损伤
  • 批准号:
    7661631
  • 财政年份:
    2008
  • 资助金额:
    $ 10.68万
  • 项目类别:
Protectan CBLB502
保护素CBLB502
  • 批准号:
    7555568
  • 财政年份:
    2008
  • 资助金额:
    $ 10.68万
  • 项目类别:
Controlling Radiation Injury by TLR5 Agonists
通过 TLR5 激动剂控制放射损伤
  • 批准号:
    8303363
  • 财政年份:
    2008
  • 资助金额:
    $ 10.68万
  • 项目类别:
Controlling Radiation Injury by TLR5 Agonists
通过 TLR5 激动剂控制放射损伤
  • 批准号:
    7897773
  • 财政年份:
    2008
  • 资助金额:
    $ 10.68万
  • 项目类别:

相似海外基金

Mechanisms that underlie the life/death decisions in a cell that activated apoptotic caspases
细胞中激活凋亡半胱天冬酶的生/死决策的机制
  • 批准号:
    10607815
  • 财政年份:
    2023
  • 资助金额:
    $ 10.68万
  • 项目类别:
Nuclear and chromatin aberrations during non-apoptotic cell death in C. elegans and mammals
线虫和哺乳动物非凋亡细胞死亡过程中的核和染色质畸变
  • 批准号:
    10723868
  • 财政年份:
    2023
  • 资助金额:
    $ 10.68万
  • 项目类别:
Non-apoptotic functions of caspase-3 in neural development
Caspase-3在神经发育中的非凋亡功能
  • 批准号:
    10862033
  • 财政年份:
    2023
  • 资助金额:
    $ 10.68万
  • 项目类别:
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
凋亡供体白细胞促进肾移植耐受
  • 批准号:
    10622209
  • 财政年份:
    2023
  • 资助金额:
    $ 10.68万
  • 项目类别:
Design of apoptotic cell mimetic anti-inflammatory polymers for the treatment of cytokine storm
用于治疗细胞因子风暴的模拟凋亡细胞抗炎聚合物的设计
  • 批准号:
    22H03963
  • 财政年份:
    2022
  • 资助金额:
    $ 10.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
  • 批准号:
    10537709
  • 财政年份:
    2022
  • 资助金额:
    $ 10.68万
  • 项目类别:
Environmental Carcinogens Induce Minority MOMP to Initiate Carcinogenesis in Lung Cancer and Mesothelioma whileMaintaining Apoptotic Resistance via Mcl-1
环境致癌物诱导少数 MOMP 引发肺癌和间皮瘤的癌变,同时通过 Mcl-1 维持细胞凋亡抵抗
  • 批准号:
    10356565
  • 财政年份:
    2022
  • 资助金额:
    $ 10.68万
  • 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
  • 批准号:
    10708827
  • 财政年份:
    2022
  • 资助金额:
    $ 10.68万
  • 项目类别:
Activation of non-apoptotic cell death by the DNA damage response
DNA 损伤反应激活非凋亡细胞死亡
  • 批准号:
    10388929
  • 财政年份:
    2022
  • 资助金额:
    $ 10.68万
  • 项目类别:
Role of natural immunity to self apoptotic exosomes in maintaining immune homeostasis
对自凋亡外泌体的自然免疫在维持免疫稳态中的作用
  • 批准号:
    RGPIN-2021-03004
  • 财政年份:
    2022
  • 资助金额:
    $ 10.68万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了